

INNOVANCE® Heparin UF Control 1

INNOVANCE

HEPARIN	UF CONTROL	1
---------	------------	---

INNOVANCE® Heparin UF Control 2

INNOVANCE

HEPARIN	UF CONTROL	2
---------	------------	---

INNOVANCE® Heparin LMW Control 1

INNOVANCE

HEPARIN	LMW CONTROL	1
---------	-------------	---

INNOVANCE® Heparin LMW Control 2

INNOVANCE

HEPARIN	LMW CONTROL	2
---------	-------------	---

I Revision bar indicates update to previous version.

Intended Use

For quality control of the INNOVANCE® Heparin assay for the quantitative determination of unfractionated heparin (UFH) and low molecular-weight heparin (LMWH) in citrated human plasma.

Remark: If not indicated otherwise, the term INNOVANCE® Heparin Controls will be used within this Instructions For Use for all controls listed above.

Summary and Explanation

Heparin (UFH and LMWH) considerably accelerates the inactivation of thrombin and coagulation factor Xa (Xa) by antithrombin (AT). For this reason UFH and LMWH preparations are widely used as prophylactic and therapeutic anticoagulants. The main clinical indications for UFH are in prevention and treatment of venous thromboembolism, in certain types of coronary artery syndrome and in thrombotic stroke. LMWH has been replacing UFH in many of the latter's traditional indications. Due to numerous influences the anticoagulant effect of an identical dose of heparin varies from patient to patient^{1,2}.

Using the INNOVANCE® Heparin assay it is possible to quantify the activity of UFH and LMWH in a patient's plasma and to verify the intended target level.

The INNOVANCE® Heparin Controls serve as quality controls for the INNOVANCE® Heparin assay.

Principles of the Procedure

The INNOVANCE® Heparin Controls consist of plasmas containing defined activities of either UFH or LMWH. Recovery of these controls within their assigned ranges indicates proper functionality of the assay system.

Reagents

Note: INNOVANCE® Heparin Controls can be used on automated coagulation analyzers. Siemens Healthineers provides Reference Guides (Application Sheets) for several coagulation analyzers. The Reference Guides (Application Sheets) contain analyzer/assay specific handling and performance information which may differ from that provided in these Instructions for Use. In this case, the information contained in the Reference Guides (Application Sheets) supersedes the information in these Instructions for Use. Please also consult the instruction manual of the instrument manufacturer!

Reagent	Description	Storage	Stability after reconstitution ^a
INNOVANCE® Heparin UF Control 1 INNOVANCE HEPARIN UF CONTROL 1 and INNOVANCE® Heparin UF Control 2 INNOVANCE HEPARIN UF CONTROL 2	With 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) stabilized and lyophilized citrated human plasma containing UFH from porcine origin. For Heparin activities please refer to the lot-specific Table of Assigned Values.	2–8 °C The controls may be used up to the expiry date indicated on the label if stored unopened.	15–25 °C: 24 hours 2–8 °C: 48 hours ≤ –18 °C ^b : 4 weeks
INNOVANCE® Heparin LMW Control 1 INNOVANCE HEPARIN LMW CONTROL 1 and INNOVANCE® Heparin LMW Control 2 INNOVANCE HEPARIN LMW CONTROL 2	With 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) stabilized and lyophilized citrated human plasma containing LMWH from porcine origin. For Heparin activities please refer to the lot-specific Table of Assigned Values.		

^a Stability claims are valid for storage in the closed original vial.

^b Reconstituted INNOVANCE® Heparin Controls can be frozen and thawed once. The controls must be frozen as rapidly as possible in the original vial. Thawing must be accomplished at 37 °C within 10 minutes. The thawed control must be used within 2 hours when stored at 15–25 °C.

Information about on-board stability is specified in the Reference Guide (Application Sheet) for the analyzer.

Warnings and Precautions

For *in-vitro* diagnostic use only.

For laboratory professional use.

Safety data sheets (MSDS/SDS) available on [siemens-healthineers.com/sds](https://www.siemens-healthineers.com/sds).

CAUTION!

Federal (USA) law restricts this device to sale by or on the order of licensed healthcare professionals.



CAUTION! POTENTIAL BIOHAZARD

Each donor or donor unit was tested and found to be negative for human immunodeficiency virus (HIV) 1 and 2, hepatitis B virus (HBV) and hepatitis C virus (HCV) using either tests that are CE marked or FDA approved for this purpose. Because no known test can offer complete assurance of the absence of infectious agents, all human derived products should be handled with appropriate caution.

Caution

This device contains material of animal origin and should be handled as a potential carrier and transmitter of disease.

Not to be used for the determination of the activity or concentration of anticoagulants other than UFH and LMWH (e.g. heparinoids, synthetic pentasaccharides, direct factor Xa inhibitors). Danger of under- or overdosing resulting in thrombotic events or bleedings, respectively.

Dispose of hazardous or biologically contaminated materials according to the practices of your institution. Discard all materials in a safe and acceptable manner and in compliance with all government requirements.

Preparing Reagents

Reconstitute INNOVANCE® Heparin Controls with the labeled amount of distilled or deionized water. Mix carefully to dissolve (without foam formation). Allow to stand at 15 to 25 °C for at least 15 minutes. Mix gently once more before use.

Procedure

Materials Provided

REF	Content	
REF OPOC05	INNOVANCE® Heparin UF Control 1 INNOVANCE HEPARIN UF CONTROL 1	5 x → 1.0 mL
REF OPOD05	INNOVANCE® Heparin UF Control 2 INNOVANCE HEPARIN UF CONTROL 2	5 x → 1.0 mL
REF OPOE05	INNOVANCE® Heparin LMW Control 1 INNOVANCE HEPARIN LMW CONTROL 1	5 x → 1.0 mL
REF OPOF05	INNOVANCE® Heparin LMW Control 2 INNOVANCE HEPARIN LMW CONTROL 2	5 x → 1.0 mL

Each pack of INNOVANCE® Heparin Controls contains a lot-specific Table of Assigned Values.

Materials Required but not Provided

Item	Description
REF OPOA05	INNOVANCE® Heparin
REF OPOB05	INNOVANCE® Heparin Calibrator
REF B4234-25	Dade® Owren's Veronal Buffer
REF OQUB21	Cleaner SCS (on BCS® XP System only)

Refer also to the Reference Guide (Application Sheet).

Test Procedure

Pipetting of controls and reagents as well as mixing and processing is performed automatically by the analyzer. For details of this processing, refer to the Instruction Manual and Reference Guide (Application Sheet).

If the values obtained are outside of the ranges, the measurement must be repeated. If the deviations are confirmed, a new calibration must be performed. Please also refer to Kitchen et al.³ for out of range results.

Results

Results are given in IU/mL.

Standardization

INNOVANCE® Heparin Controls are traceable to the WHO (World Health Organization) International Standards for UFH and LMWH.

Technical Assistance

























For customer support, contact your local technical support provider or distributor.
siemens-healthineers.com

References

1. Hirsh J, Raschke R. Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
2. Gray E, Mulloy B, Barrowcliffe T W, Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818
3. Kitchen S, Preston FE, Olson JD. Internal quality control in the hemostasis laboratory. In: Kitchen S, Olson JD, Preston FE, editors. Quality in Laboratory Hemostasis and Thrombosis. 2nd ed. Wiley-Blackwell; 2013. P.57-64.

Definition of Symbols

The following symbols may appear on the product labeling:

	Do not reuse		Use By
	Batch Code		Catalogue Number
	Caution		Manufacturer
	Authorized representative in the European Community		Contains sufficient for <n> tests
	Biological Risks		<i>In Vitro</i> Diagnostic Medical Device
	Temperature Limitation		Consult instruction for Use
	Non-sterile		CE marking of conformity
	CE marking of conformity with notified body ID number. Notified body ID number can vary.		Contents
	Reconstitution volume		Level
	Keep away from sunlight and heat		Warning
	Danger		Prescription device (US only)
	Device Identification (UDI) barcode	 xx/xx/xx	REACH Authorization Number

Legal Information

BCS, Dade and INNOVANCE are trademarks of Siemens Healthineers.

All other trademarks are the property of their respective owners.

© Siemens Healthineers, 2016–2021. All rights reserved.

Siemens Healthineers Headquarters

Siemens Healthcare GmbH
Henkestraße 127
91052 Erlangen
Germany
Phone: +49 9131 84-0
siemens-healthineers.com



Siemens Healthcare Diagnostics Products GmbH

Emil-von-Behring-Str. 76
35041 Marburg
Germany
siemens-healthineers.com